Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Potential Mechanism of Exercise Impairment in OSA

3. Januar 2018 aktualisiert von: Robert L. Owens, University of California, San Diego

Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea

Obstructive sleep apnea (OSA) is a common disorder with major cardiovascular sequelae. A recent study confirmed that OSA is associated with impaired exercise capacity and increasing OSA severity predicts worsening exercise capacity, which is a marker of potential increased cardiovascular risk. However, potential mechanisms of decreased exercise capacity caused by OSA remain unclear. Several pathophysiologic mechanisms of OSA have been proposed and investigators hypothesize that endothelial dysfunction leading to exercise-induced right ventricular dysfunction and associated pulmonary hypertension is the potential mechanism for impaired exercise capacity in OSA.

Studienübersicht

Status

Abgeschlossen

Detaillierte Beschreibung

Obstructive sleep apnea (OSA) is a common disorder with major cardiovascular sequelae, including increased systemic hypertension and strokes. OSA is highly prevalent among patients with cardiovascular disease (CVD), but OSA remains under-diagnosed, thus under-treated. Furthermore, a recent study confirmed that OSA is associated with impaired exercise capacity and increasing OSA severity predicts worsening exercise capacity, which is a marker of potential increased cardiovascular risk. However, potential mechanisms of decreased exercise capacity caused by OSA remain unclear.

Several pathophysiologic mechanisms of OSA have been proposed to explain this observation. Endothelial dysfunction is one mechanism that may result from OSA-related intermittent hypoxemia, heightened sympathetic activation, and increased blood pressure. Endothelial dysfunction is characterized by alteration of normal endothelial physiology consisting of a reduction in the bioavailability of vasodilators such as nitric oxide leading to impaired endothelium-depended vasodilation. Endothelial dysfunction has been consistently associated with an increased incidence of CVD. Recent evidence also suggests a correlation between endothelial function and exercise capacity.

In addition, endothelial dysfunction of pulmonary vasculature play an integral role in the pathogenesis of pulmonary hypertension (PH), which is defined by a mean pulmonary artery pressure exceeding 25 mm Hg. PH is associated with increased mortality and multiple morbidities including impaired exercise capacity. OSA has been formally recognized as a cause of PH by the World Health Organization (WHO) and the estimated prevalence of PH in patients with OSA is 17%. Repetitive nocturnal hypoxemia, increased sympathetic tone, and diminished endothelial dependent vaso-reactivity contribute to pulmonary artery hypoxic vasoconstriction, subsequently leading to pulmonary vasculature remodeling and PH. Recently, PH induced by exercise was described as part of the PH spectrum and may represent early, mild, PH that is still clinically relevant in many patients. To detect early PH in OSA patients may signify the importance of treatment and compliance for newly diagnosed OSA patients.

In summary, our hypothesis is that OSA patients may have endothelial dysfunction that leads to impaired exercise capacity via exercise-induced pulmonary hypertension. If our hypothesis is correct, non-invasive measurements of endothelial function could be used clinically to risk stratify patients or follow response to treatment.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

29

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • San Diego, California, Vereinigte Staaten, 92093
        • University of California, San Diego

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Investigators will enroll 30 subjects with OSA (OSA group) and 30 subjects without OSA (control group). The detailed inclusion and exclusion criteria for subjects are listed below. Female subjects will be offered a urinary pregnancy test and only those documented to be non-pregnant will be studied.

Beschreibung

Inclusion Criteria:

  • BMI < 30
  • OSA group: diagnosis of untreated moderate-to-severe OSA (apnea-hypopnea index (AHI) ≥ 15 events/h).
  • Control group: no OSA (AHI < 5 events/h).

Exclusion Criteria:

  • Currently using Continuous Positive Airway Pressure (CPAP) or oral appliance treatment for OSA
  • Uncontrolled cardiac co-morbidity, e.g. ischemic heart disease, heart failure, or valvular heart disease that would prevent exercise
  • Uncontrolled pulmonary co-morbidity, e.g. asthma or chronic obstructive pulmonary disease (COPD)
  • Comorbidities that may severely impair peripheral circulation, e.g. uncontrolled diabetes mellitus, or systemic scleroderma
  • Neurological conditions limiting the ability to perform walking or cycling
  • Orthopedic condition limiting the ability to perform walking or cycling
  • Current smokers, alcohol (> 3 oz/day) or use of illicit drugs.
  • Psychiatric disorder, other than mild and controlled depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.
  • Pregnancy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
OSA Group
Apnea-hypopnea index (AHI) ≥ 15 events/h
Control Group
Apnea-hypopnea index (AHI) < 5 events/h

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Endothelial function, as measured by endoPAT, between OSA patients and matched healthy controls
Zeitfenster: Baseline
EndoPAT is a non-invasive measurement of endothelial function, using peripheral arterial tonometry. Exercise tolerance is measured by Cardiopulmonary exercise testing (CPET). Effects of OSA on exercise tolerance and endothelial function will be evaluated.
Baseline

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Right ventricular systolic pressure (RVSP) in response to exercise
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Pulmonary systolic pressure (PASP) in response to exercise
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Right ventricular outflow track (RVOT) peak velocity in response to exercise
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Velocity time interval (VTI) in response to exercise
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Pulmonary artery acceleration time in response to exercise
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Systolic peak tricuspid myocardial annular velocity
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Diastolic peak tricuspid myocardial annular velocity
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Peak tricuspid myocardial annular velocity during isovolumic contraction
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Peak tricuspid myocardial annular velocity during isovolumic relaxation
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Right ventricular (RV) wall stress
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
3-D right ventricular ejection fraction (3D-RVEF)
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Systolic peak right ventricular (RV) strain
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Early diastolic peak right ventricular (RV) strain
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline
Late diastolic peak right ventricular (RV) strain
Zeitfenster: Baseline
Measured by Echocardiogram, between OSA patients and matched healthy controls
Baseline

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Juli 2015

Primärer Abschluss (Tatsächlich)

9. Mai 2017

Studienabschluss (Tatsächlich)

9. Mai 2017

Studienanmeldedaten

Zuerst eingereicht

12. Juli 2015

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. Juli 2015

Zuerst gepostet (Schätzen)

22. Juli 2015

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Januar 2018

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. Januar 2018

Zuletzt verifiziert

1. Januar 2018

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Obstruktive Schlafapnoe

  • Elsan
    European Clinical Trial Experts Network; Polyclinique Poitiers
    Abgeschlossen
    Obstruktives Schlafapnoe-Syndrom | Hypnose | Drug Induce Sleep Endoscopy
    Frankreich
  • Brigham and Women's Hospital
    Charite University, Berlin, Germany; Stanford University
    Rekrutierung
    Schlafstörungen, intrinsisch | Schlaf-Wach-Störungen | Schlafstörungen, zirkadianer Rhythmus | Fortgeschrittenes Schlafphasensyndrom (ASPS) | Verzögertes Schlafphasensyndrom | Schichtarbeits-Schlafstörung | Verzögerte Schlafphase | Nicht-24-Stunden-Schlaf-Wach-Störung | Fortgeschrittenes Schlafphasensyndrom und andere Bedingungen
    Vereinigte Staaten
3
Abonnieren